![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
20
Ind-swift Laboratories Limited Chandigarh In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Telmisartan, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2010-373 - Rev 02
This Chemical Type CEP, issued on February 12, 2016, remains in force until June 19, 2017, ensuring its reliability within the pharmaceutical industry.
Substance Number 2154 associated with this CEP further emphasizes